Single-agent therapy with bicalutamide: A comparison with medical or surgical castration in the treatment of advanced prostate carcinoma

Chodak, Gerald W.; Sharifi, R.; Kasimis, Basil; Block, Norman L.; Macramalla, Effat A.; Kennealey, Gerard T.

doi:10.1016/s0090-4295(99)80356-2

Cited by 73 publications

(60 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…26,27,35,36,39,44,46 This measure, specifically validated on advanced metastatic prostate patients, consists of 30 questions addressing 10 relevant do- 31 the Functional Living Index-Cancer, 45 the Southwest Oncology Group questionnaire (SWOG), 29 and the Functional Assessment of Cancer Therapy. 32 Nevertheless, some trials reported limited information about the nature of the HRQOL measure used while others created ad hoc measures without giving any information about the developmental process.…”

Section: Hrqol Assessment Methodologymentioning

confidence: 99%

“…Ten RCTs were carried out in North America, [25][26][27][28][29][30][31][32][33][34] nine were carried out in Europe, [35][36][37][38][39][40][41][42][43] three enrolled patients from different continents, 44 -46 and three were carried out in Japan. [47][48][49] Bicalutamide, the therapy against which most treatment comparisons were made, was used in seven trials.…”

Section: Demographics and Trial Designsmentioning

confidence: 99%

“…[47][48][49] Bicalutamide, the therapy against which most treatment comparisons were made, was used in seven trials. 26,27,35,36,39,44,46 Radiotherapy was limited to four RCTs. 25,31,42,47 The majority of the trials involved metastatic prostate carcinoma patients aged 65-75 years.…”

Section: Demographics and Trial Designsmentioning

confidence: 99%

“…There was partial consensus on the benefits of bicalutamide on some HRQOL domains, though most of these studies gave either limited details on compliance at baseline or did not report compliance data, thus hampering a robust conclusion regarding the impact of bicalutamide on HRQOL. 26,35,36,44,46 Iversen et al 36 reported that sexual interest was greater in patients treated with bicalutamide at one month; pain and bed disability outcomes improved more in the orchidectomy group at one and three months. Emotional well being and social functioning improved more in patients randomized to orchidectomy at three and six months after entry, respectively.…”

Section: Clinical Impact Of Medical Treatment Modalities On Patient Hmentioning

confidence: 99%

See 3 more Smart Citations

Health related quality of life in prostate carcinoma patients

Efficace

Bottomley

Andel

2003

Cancer

View full text Add to dashboard Cite

Extensive lattice‐Boltzmann simulations were performed to obtain the drag force for random arrays of monodisperse and bidisperse spheres. For the monodisperse systems, 35 different combinations of the Reynolds number Re (up to Re = 1,000) and packing fraction ϕ were studied, whereas for the bidisperse systems we also varied the diameter ratio (from 1:1.5 to 1:4) and composition, which brings the total number of different systems that we considered to 150. For monodisperse systems, the data was found to be markedly different from the Ergun equation and consistent with a correlation, based on similar type of simulations up to Re = 120. For bidisperse systems, it was found that the correction of the monodisperse drag force for bidispersity, which was derived for the limit Re = 0, also applies for higher‐Reynolds numbers. On the basis of the data, a new drag law is suggested for general polydisperse systems, which is on average within 10% of the simulation data for Reynolds numbers up to 1,000, and diameter ratios up to 1:4. © 2007 American Institute of Chemical Engineers AIChE J, 2007.

show abstract

Section: Hrqol Assessment Methodologymentioning

confidence: 99%

Section: Demographics and Trial Designsmentioning

confidence: 99%

Section: Demographics and Trial Designsmentioning

confidence: 99%

Section: Clinical Impact Of Medical Treatment Modalities On Patient Hmentioning

confidence: 99%

See 2 more Smart Citations

Health related quality of life in prostate carcinoma patients

Efficace

Bottomley

Andel

2003

Cancer

View full text Add to dashboard Cite

show abstract

“…The effects of pure anti-androgen treatment have been compared to those of medical or surgical castration in randomized trials in men with metastatic prostate cancer. Although these drugs seem to be better tolerated, they are inferior therapies in terms of overall and progression-free survival 33,34 .…”

Section: Boxmentioning

confidence: 99%

A history of prostate cancer treatment

2002

View full text Add to dashboard Cite

The increased incidence of prostate cancer has led to remarkable changes in diagnosis and treatment over the past century. What were the first ways in which prostate cancer was treated, and how did these evolve into the variety of therapeutic strategies from which patients have to choose today?In 1853, J. Adams, a surgeon at The London Hospital, described the first case of prostate cancer, which he discovered by histological examination 1 . Adams noted in his report that this condition was "a very rare disease". Remarkably, 150 years later, prostate cancer has become a significant health problem. In the United States, it is the most commonly diagnosed cancer in men, with 180,000 new cases and about 31,000 deaths occurring annually 2 . This dramatic increase in the number of prostate cancer cases can be attributed to several causes. First, prostate cancer was not differentiated from other types of urinary obstruction until the early 1900s. Second, the incidence of prostate cancer increases more rapidly with age than any other cancer type 2 . The number of cases has risen as the average life expectancy has increased over the past century. Third, the increased incidence seems to be, in some way, related to the 'Western' lifestyle: the incidence of clinical prostate cancer is significantly lower in Asian populations, compared with Western populations 3 , and it

show abstract

Bicalutamide (Casodex®) in the treatment of prostate cancer: History of clinical development

1998

View full text Add to dashboard Cite

BACKGROUND Bicalutamide (Casodex®) is a new nonsteroidal antiandrogen developed for use in patients with prostate cancer. The efficacy and tolerability of bicalutamide as monotherapy and as combination therapy for patients with advanced prostate cancer have been evaluated in randomized clinical trials. Clinical trials are currently in progress to further evaluate bicalutamide as monotherapy in patients with advanced stages of disease and as adjuvant or first‐line therapy in patients with early‐stage disease. METHODS A review of published trials of bicalutamide focusing on dose‐ranging investigations, phase II and phase III monotherapy trials, a phase III trial of combined androgen blockade, and a safety overview. RESULTS In dose‐ranging trials, bicalutamide doses of 10‐200 elicited biochemical, objective, and subjective responses; higher bicalutamide doses (up to 600 mg) have also been evaluated. A 50‐mg daily dose of bicalutamide was initially evaluated as monotherapy in phase II and phase III trials; in subsequent trials, a 150‐mg daily dose was investigated. A 150‐mg daily dose is considered to provide equivalent survival outcome compared with castration in patients with locally advanced prostate cancer, whereas the benefits of a better quality of life and better palliation with the 150‐mg daily bicalutamide dose relative to castration in patients with metastatic disease needs to be balanced against the small shortfall (median difference, 42 days) in survival. In combination with a luteinizing hormone‐releasing hormone agonist analogue (LHRH‐A), a 50‐mg daily dose of bicalutamide has equivalent efficacy to a corresponding flutamide (250 mg three times daily) combination regimen. Treatment with the bicalutamide combination regimen resulted in a longer median survival than with the flutamide combination regimen. Bicalutamide is well tolerated when used as monotherapy or in combination with a LHRH‐A. The benefits of bicalutamide as monotherapy include retention of libido and sexual potency and as combination therapy a lower incidence of diarrhea relative to flutamide. CONCLUSIONS A 50‐mg daily dose of bicalutamide is sufficient when given in combination with an agent, such as a LHRH‐A, that lowers serum testosterone, but higher doses of bicalutamide may be needed when the drug is given as monotherapy. Bicalutamide, 50‐mg daily, is a logical first choice for antiandrogen therapy when used in combination with an LHRH‐A for the treatment of patients with advanced prostate cancer. Bicalutamide 150‐mg daily is considered an effective monotherapy for use in patients with locally advanced disease. Additional clinical trials are currently in progress to further evaluate bicalutamide as a monotherapy for advanced prostate cancer and to assess its value as adjuvant or first‐line therapy for early‐stage prostate cancer. Prostate 34:61–72, 1998. © 1998 Wiley‐Liss, Inc.

show abstract

Single-agent therapy with bicalutamide: A comparison with medical or surgical castration in the treatment of advanced prostate carcinoma

Cited by 73 publications

References 15 publications

Health related quality of life in prostate carcinoma patients

Health related quality of life in prostate carcinoma patients

A history of prostate cancer treatment

Bicalutamide (Casodex®) in the treatment of prostate cancer: History of clinical development

Contact Info

Product

Resources

About